RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit
04 janv. 2021 11h00 HE
|
RadioMedix Inc.
Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for...
Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic
02 déc. 2020 08h03 HE
|
TARGIT Collaborative Group (TCG)
SACRAMENTO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- The TARGIT Collaborative Group announced today that according to recent studies, an increase in the COVID-19 positivity rate correlates to an...
RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)
03 janv. 2020 00h00 HE
|
RadioMedix Inc.
Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...
RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.
22 janv. 2019 10h00 HE
|
RadioMedix Inc.
Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
13 nov. 2018 10h00 HE
|
RadioMedix Inc.
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
10 janv. 2018 05h00 HE
|
RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
22 juin 2017 16h00 HE
|
RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
Viewpoint MT and RadioMedix secured a second SBIR NCI grant for image guided therapy of metastatic melanoma
27 août 2015 00h00 HE
|
RadioMedix Inc.
Houston, TX, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Viewpoint Molecular Targeting LLC.(Iowa City, IO) and RadioMedix Inc. (Houston TX) partnership resulted in the second Small Business Innovation...